ANALYST-UPGRADE ·Filed Oct 15, 2026
UBS double upgrade: Neutral → Buy
Price Chart
Loading chart...
Executive Summary
UBS double upgrade: Neutral → Buy
Impact Score
Base Score
4/7
LLM Adjustment
+0
Final Score
4/10
Consensus & Targets
Buy / Strong Buy
26 (68%)
Hold
12
Sell / Strong Sell
0
Total Analysts
26
Mean PT
$859.69
Median PT
$857.00
High PT
$1,030.00
Low PT
$730.00
Current Price
$778.36
Implied Upside
+10.4%
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-15 | UBS | upgrade | Buy | $978.00 |
| 2026-10-08 | RBC Capital | maintain | Sector Perform | $810.00 |
| 2026-10-07 | Truist Securities | maintain | Buy | $780.00 |
| 2026-10-07 | Morgan Stanley | maintain | Equal-Weight | $779.00 |
| 2026-10-06 | JP Morgan | maintain | Overweight | $950.00 |
| 2026-10-01 | Jefferies | maintain | Buy | $930.00 |
| 2026-10-01 | Argus Research | upgrade | Buy | $850.00 |
| 2026-09-29 | RBC Capital | reiterate | Sector Perform | $737.00 |
| 2026-09-10 | HSBC | maintain | Buy | $920.00 |
| 2026-08-17 | Leerink Partners | maintain | Market Perform | $824.00 |
Firm Track Record — UBS
UBS accuracy: 55% on 5070 calls | avg return: 4.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| UBS | 67% | 4/6 | 5.1% | top tier |
| Canaccord Genuity | 57% | 4/7 | 9.4% | above average |
| TD Cowen | 50% | 1/2 | 3.1% | below average |
| Bernstein | 50% | 1/2 | 6.2% | below average |
| Cantor Fitzgerald | 50% | 4/8 | -4.5% | below average |
| BMO Capital | 50% | 3/6 | -3.7% | below average |
| Morgan Stanley | 50% | 5/10 | 4.1% | below average |
| Goldman Sachs | 50% | 1/2 | -3.6% | below average |
| Leerink Partners | 50% | 1/2 | -23.7% | below average |
| Evercore ISI Group | 50% | 1/2 | -4.9% | below average |
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $19.13 | $14.35 — $24.48 | $5.1B | ↑4 ↓0 |
| +1y | $51.03 | $42.52 — $57.25 | $18.6B | ↑0 ↓0 |
| 0q | $16.07 | $14.78 — $17.68 | $4.5B | ↑0 ↓0 |
| 0y | $57.64 | $43.42 — $64.58 | $17.4B | ↑3 ↓0 |
Cross-Platform Signals
Insider Trades (90d)
0 buys / 5 sells
Institutional
Assenagon Asset Management S.A. — near_exit (-84.9%)
Institutional
Farther Finance Advisors, LLC — add (42.7%)
Institutional
MANUFACTURERS LIFE INSURANCE COMPANY, THE — trim (-63.8%)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
Report based on filing metadata.
27 reports for REGN
85% Hit rate best @ T+60▲ +26.47%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 3d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Oct 1, 2026 17d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 6w ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $790.74 (−6.25%) |
Aug 24, 2026 8w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $790.74 (−4.56%) |
Aug 20, 2026 8w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $790.74 (−4.34%) |
Aug 12, 2026 9w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $790.74 (−0.91%) |
Aug 11, 2026 9w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $790.74 (−0.79%) |
Jul 30, 2026 11w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $790.74 (+7.10%) |
Jul 30, 2026 11w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $790.74 (+7.10%) |
Jul 27, 2026 11w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $790.74 (−13.75%) |
Showing 10 of 27
US Market Status
Market Closed — Opens in 6h 33m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access